Felvizumab, identified by the CAS number 167747-20-8, is a monoclonal antibody that was developed for therapeutic applications, particularly in the context of autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, it is designed to target specific antigens, thereby modulating immune responses. The structure of Felvizumab allows it to bind selectively to its target, which can lead to the inhibition of pathological processes associated with disease states. Its mechanism of action typically involves blocking receptor-ligand interactions or neutralizing pathogenic factors. The pharmacokinetics of Felvizumab may include a relatively long half-life, allowing for less frequent dosing compared to smaller molecules. Additionally, like other monoclonal antibodies, it may exhibit immunogenicity, which can affect its efficacy and safety profile. Overall, Felvizumab represents a class of biologic therapies that leverage the specificity of antibodies to provide targeted treatment options in complex diseases.

Felvizumab

167747-20-8: Felvizumab, identified by the CAS number 167747-20-8, is a monoclonal antibody that was developed for therapeutic applications, particularly in the context of autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, it is designed to target specific antigens, thereby modulating immune responses. The structure of Felvizumab allows it to bind selectively to its target, which can lead to the inhibition of pathological processes associated with disease states. Its mechanism of action typically involves blocking receptor-ligand interactions or neutralizing pathogenic factors. The pharmacokinetics of Felvizumab may include a relatively long half-life, allowing for less frequent dosing compared to smaller molecules. Additionally, like other monoclonal antibodies, it may exhibit immunogenicity, which can affect its efficacy and safety profile. Overall, Felvizumab represents a class of biologic therapies that leverage the specificity of antibodies to provide targeted treatment options in complex diseases.

Felvizumab (SB 209763), a humanized IgG1κ monoclonal antibody, targets specific neutralizing epitopes on the F glycoprotein of Respiratory Syncytial Virus (RSV

Human-mouse monoclonal g-chain anti-respiratory syncytial immunoglobulin G1.

CAS 167747-20-8

Felvizumab

Felvizumab

Ref: TM-T77005

Felvizumab

Ref: 3D-CLA1077